EU trade policies regulating the pharmaceutical industry, including the seizure of generic drugs in transit to developing countries, are supporting the commercial interests of some drugmakers while damaging opportunities for innovation and access to medicines in developing countries, an Oxfam International and Health Action International (HAI) report says. The report criticizes recent European customs authorities’ seizures of generic drugs suspected of infringing intellectual property rights.
- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
-
Biosimilars
News
- Canada approves pegfilgrastim biosimilar Pexegra
- Insulin aspart and denosumab biosimilars approved in US
- FDA approves tocilizumab biosimilar Avtozma
- January 2025 biosimilar approvals in Europe
- MORE EDITORIAL SECTIONS
- Search
Post your comment